Geron Raises 2024 Revenue Guidance Amid RYTELO Growth

Geron Corporation (GERN) raised its full-year 2024 net revenue guidance to a mid-to-high $230 million–$240 million range, following a strong first half of 2024 marked by 24% year-over-year growth in RYTELO’s sales. The company’s Q2 2024 net revenue reached $57.5 million, up nearly $5 million from Q1, marking three consecutive quarters of sequential growth. Operating expenses for 2024 are also projected at $230 million–$240 million, reflecting a 4% year-to-date decline in costs. Geron ended the period with over $327 million in cash, avoiding final drawdowns on its $125 million Pharmakon debt facility. Market capitalization stood at approximately $973 million as of recent reports. The telomerase inhibitor RYTELO, indicated for lower-risk myelodysplastic syndrome (MDS), is positioned as a key driver of growth, with about 80% of patients treated in community settings—a primary commercial focus. Second-line use remains the primary target under updated NCCN guidelines, where RYTELO is preferred over hypomethylating agents. Geron’s myelofibrosis Phase III trial, targeting relapsed/refractory patients who failed JAK inhibitors, is nearing completion, with an interim overall survival analysis expected by the end of 2024 and a final analysis projected for the second half of 2028. International commercialization plans for RYTELO outside the U.S. are expected by year-end 2024, with models including partnerships and contract sales organizations to avoid large-scale field forces in Europe. Geron’s CEO emphasized the drug’s transformative potential, noting that success in myelofibrosis could redefine patient outcomes and the company’s trajectory. The gross-to-net discount for RYTELO is expected to remain in the mid-20% range through 2024, with potential increases as volume grows. Comparatively, BMS’s luspatercept peaked at about $2.5 billion in sales, with $500 million from non-U.S. markets, highlighting the commercial scale Geron aims to achieve with RYTELO.